# Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects

> **NCT03928353** · PHASE2 · COMPLETED · sponsor: **SFJ Pharmaceuticals, Inc.** · enrollment: 23 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** PB2452 Infusion
- **DRUG:** Placebo - Sodium Chloride
- **DRUG:** Ticagrelor Oral Tablet - Pre-Treatment
- **DRUG:** Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
- **DRUG:** Ticagrelor Oral Tablet - Pre-Treatment
- **DRUG:** PB2452 Infusion
- **DRUG:** Placebo - Sodium Chloride

## Key facts

- **NCT ID:** NCT03928353
- **Lead sponsor:** SFJ Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2019-10-09
- **Final completion:** 2019-10-09
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2024-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03928353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03928353, "Study to Evaluate the Safety, Tolerability, PK and PD of PB2452 in Healthy Younger, Older and Elderly Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03928353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*